Buying Royalty Streams on the Cheap

How much do you trust management to invest your cash? That's a question you have to ask of any company with a stockpile of cash. But it's especially important for investors in PDL Biopharma (Nasdaq: PDLI  ) , in which management doesn't have much else to do.

PDL was split off from its drug developing sister, Facet Biotech, which Abbott Labs (NYSE: ABT  ) eventually bought. What's left in PDL is a set of patents that contribute revenue from drugmakers producing humanized monoclonal antibody drugs. Roche's Herceptin, Lucentis, and Avastin, and Tysabri from Elan (NYSE: ELN  ) and Biogen Idec (Nasdaq: BIIB  ) all contributed to the $83 million that PDL brought in during the first quarter.

Having resolved patent disputes with AstraZeneca (NYSE: AZN  ) , UCB, and Novartis (NYSE: NVS  ) over the last few months, PDL is all set to collect its royalties and pay out the cash at a dividend that currently sits at 9.7%.

Except PDL has $193 million in cash that management is planning on using to acquire additional royalty streams. Like those late-night commercials offering to give you up-front cash in exchange for signing over your monthly lawsuit settlement payments, PDL is looking for desperate universities or drug companies that would rather have cash now than payments over time.

There are certainly opportunities available. A few years ago, Vertex Pharmaceuticals (Nasdaq: VRTX  ) monetized the royalty stream it was getting from GlaxoSmithKline for HIV treatment Lexiva, which it helped develop and was collecting royalties on.

The trick is to find patents that are secure and a royalty stream that's predictable. The former requires good lawyers; the latter can be a bit of a gamble. Who knows how sales of a drug are going to pan out over the five or 10 years that might be left on a royalty stream?

If management makes good choices, PDL could be worth more than where investors are currently valuing it. Just realize that the dividend will have to increase or PDL will have to return assets to investors in order for investors to make back their current investment before the current patent portfolio expires in December 2014.

Elan and Vertex are Motley Fool Rule Breakers picks. GlaxoSmithKline and Novartis are Motley Fool Global Gains choices. The Fool owns shares of Abbott and GlaxoSmithKline. Alpha Newsletter Account, LLC owns shares of Abbott. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (8)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 1484259, ~/Articles/ArticleHandler.aspx, 7/31/2014 6:33:50 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement